We are live on ! Find out more
ABBV icon

AbbVie

3,374 hedge funds and large institutions have $217B invested in AbbVie in 2024 Q2 according to their latest regulatory filings, with 155 funds opening new positions, 1,472 increasing their positions, 1,318 reducing their positions, and 126 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $2.77B | Put options by funds: $2.09B

32% more capital inflows, than outflows

Capital inflows: $9.17B | Capital outflows: $6.95B

23% more first-time investments, than exits

New positions opened: 155 | Existing positions closed: 126

12% more repeat investments, than reductions

Existing positions increased: 1,472 | Existing positions reduced: 1,318

0.55% more ownership

Funds ownership: 71.12% → 71.67% (+0.55%)

0% less funds holding

Funds holding: 3,390 → 3,374 (-16)

21% less funds holding in top 10

Funds holding in top 10: 223 → 177 (-46)

Holders
3,374
Holders Change
-16
Holders Change %
-0.47%
% of All Funds
48.6%
Holding in Top 10
177
Holding in Top 10 Change
-46
Holding in Top 10 Change %
-20.63%
% of All Funds
2.55%
New
155
Increased
1,472
Reduced
1,318
Closed
126
Calls
$2.77B
Puts
$2.09B
Net Calls
+$686M
Net Calls Change
-$48.9M

ABBV Hedge Fund Activity: Q2 2024 in Review

3,374 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2024, worth a combined $217B — down 5% from $228B a quarter earlier.

Buyers outnumbered sellers: 155 funds opened new ABBV positions and 126 closed out — a net gain of 29 holders — while 1,472 added to existing stakes and 1,318 trimmed.

The largest buyer was Capital World Investors, adding an estimated $979M. The largest seller was Capital International Investors, cutting an estimated $1.57B.

  • 3,374 institutional investors held AbbVie (ABBV) as of Q2 2024, down from 3,390 in Q1 2024.
  • Funds reported $217B of AbbVie stock for Q2 2024, down 5% quarter-over-quarter.
  • 155 funds opened new AbbVie positions in Q2 2024 and 126 closed out, a net change of +29 holders.
  • The largest AbbVie buyer in Q2 2024 was Capital World Investors, an estimated $979M added.
  • The largest AbbVie seller in Q2 2024 was Capital International Investors, an estimated $1.57B sold.

Based on aggregated 13F filings for Q2 2024.